Navigation Links
Challenging the Norm May Lead to New Therapy for Type 2 Diabetes
Date:3/20/2008

GRAND RAPIDS, Mich., March 20 /PRNewswire/ -- What happens when leading biochemists get together to challenge conventional pharmaceutical theories? Often, incredible new drug therapies are born. Recently, this same scenario began when two former major pharma scientists challenged the concept behind the leading treatments for type 2 diabetes, a disease that impacts millions of Americans. They saw the side effects caused by the current therapy like high blood pressure and weight gain, and went to work on a hypothesis that the current receptor was leading to these side effects associated with PPAR-based therapies.

As non-conventional as the theory was, it's working. Drs. Jerry Colca and Rolf Kletzien, co-founders of Kalamazoo, Michigan-based Metabolic Solutions Development Company (MSDC), have completed Phase I clinical studies and just received second phase funding from a Michigan-based science fund. They have applied for an FDA fast-track review of their work.

"We are pleased that our lead compound performed so well in Phase I studies," said Colca, MSDC's chief scientific officer. "Pre-clinical studies suggest that this compound can deliver significant pharmacological benefit without the complications inherent in current PPAR-based therapies."


'/>"/>
SOURCE Metabolic Solutions Development Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
8. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
9. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
... Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader ... Tech International (PTI), a joint venture of its subsidiary ... sales agreement with Cure Hands, a company of international ... agreement, Pharma Tech International, the exclusive distributor of CellerateRX® ...
... May 16, 2011 UBM Canon,s medical device publishing ... for the remainder of 2011. (Logo: ... an exciting list of comprehensive content topics that encompass ... outsourcing," stated Rich Nass, Director of Content for the ...
Cached Medicine Technology:International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 2International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 3International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 4UBM Canon Medical Device Content Team Announces Upcoming Virtual Event Content Topics 2UBM Canon Medical Device Content Team Announces Upcoming Virtual Event Content Topics 3
(Date:7/11/2014)... Obese and overweight firefighters are not receiving weight ... to new research from The University of Texas ... guidelines state that health care professionals (HCPs) should ... healthy weight. Firefighters have high rates of obesity, ... line-of-duty deaths in firefighters. This study assessed the ...
(Date:7/11/2014)... NY (PRWEB) July 11, 2014 The ... the five years to 2014 on the heels of ... 2010 prompted farmers to dedicate a larger share of ... production. More specifically, the regulations required the mixing of ... expanding biofuel production in the United States created a ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... from the worldwide scourge of dengue fever was somewhat successful ... only prevented dengue fever in 56 percent of the 10,000 ... protected more than 88 percent of them from severe disease. ... and sometimes death. "This vaccine has already proven to ...
(Date:7/11/2014)... July 11, 2014 Ticket Down is a reliable ... in Mountain View, CA. Over the years Luke Bryan has ... Not only does he do well at award shows, but each ... the most anticipated tours of the genre and this summer is ... artists can compare to the popularity and success that is currently ...
(Date:7/11/2014)... Riverside Health System became the first provider of ... late 2012 and now, in partnership with Williamsburg Landing, will ... Williamsburg and Newport News region. , Also known as life ... independent older adults who wish to remain in their homes ... continuing care services as well as control over the cost ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... New Survey Indicates that a Patient,s or Loved One,s Hearing ... to Inefficiency and ... Hearing loss among those,who require the assistance of a caregiver ... providing care, according to a new survey,released by Songbird Hearing, ...
... Winners Can Receive Up to $15,000 Each to Donate to Nonprofit of Their ... ... The deadline to submit,nominations for this year,s Welcome Back Awards, a national awards ... are now due by Monday, December 15, 2008., The Welcome Back Awards ...
... Calif., Nov. 12 Forterus,Inc. (OTC Bulletin Board: FTER) ... back up to $20,000 in stock in open market,transactions., ... is severely,undervalued, and does not reflect the financial success ... past two months," said,Paul Howarth, CEO of Forterus., ...
... Study Links Quercetin To Reduced Risk for Respiratory Infection, ... for a natural,way to stay well this cold and ... of today,s hottest "Super Fruits." In conjunction with,the typical ... known for its natural anti-viral activity and found in ...
... Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical company ... diseases,reported corporate and clinical program updates for the ... The updates were given during,a podium presentation by ... web,cast at the Rodman & Renshaw 10th Annual ...
... of the Place They Live , ... Alpharetta, Ga. (Vocus) November 12, ... headquarters on October 17, 2008. The building houses the six operating ... Associates had significant input into the design of the building from ...
Cached Medicine News:Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 2Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 3Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 4Health News:Deadline Extended to Submit Nominations for Depression Awards Program 2Health News:Deadline Extended to Submit Nominations for Depression Awards Program 3Health News:Forterus Inc. Announces Stock Buyback 2Health News:New Research Shows Specific Antioxidant, Found in Cherries, May Boost the Body's Defenses Against the Flu 2Health News:EntreMed Reports Clinical Program Progress and Company Update 2Health News:EntreMed Reports Clinical Program Progress and Company Update 3Health News:EntreMed Reports Clinical Program Progress and Company Update 4Health News:EntreMed Reports Clinical Program Progress and Company Update 5Health News:Jackson Healthcare Dedicates New Corporate Headquarters 2Health News:Jackson Healthcare Dedicates New Corporate Headquarters 3
... The Xact stent is self-expanding and has ... yet highly flexible mesh intended to help restore ... a smooth inner vessel surface, and potentially reduce ... diseased vessel when it is treated, which can ...
... Super Premium ALPHA 10 System offers ... in an intuitive and ergonomically designed ... ideal system for Perinatology/Maternal & Fetal ... Applications, Breast Imaging, and General Imaging ...
... (hGH; somatotropin) is a 22 kD, 191 amino ... of the anterior pituitary. The hGH gene contains ... five members of a gene family. The hGH ... of hGH released into the cell culture supernatant ...
... is the sulfate ester of DHEA, derived ... of DHEA in adrenal and extradrenal tissues. ... by the adrenal cortex, and is a ... possesses relatively weak androgenic activity, which for ...
Medicine Products: